1. Scrip
  2. >>Focus On Asia

Alteogen, 3SBio Agree Pact For ‘Biobetter’ Trastuzumab ADC

 
• By Jung Won Shin

Chinese biotech 3SBio has licensed greater China rights to Alteogen’s novel trastuzumab-containing antibody-drug conjugate for breast cancer, in a deal that will expand 3SBio’s biologics pipeline and eventually provide competition in the indication to major firms including Roche.

SEOUL – South Korea’s Alteogen Inc. has inked an exclusive licensing deal with 3SBio Inc., a leading China-based biotechnology company, for the development, manufacturing and marketing of ALT-P7, a novel antibody-drug conjugate (ADC) for treating HER2-positive breast cancer.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Focus On Asia

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.